Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net income		$ 410,607	$ 222,238
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		30,445	26,747
Amortization of intangible assets		32,237	23,340
Amortization of original issue discount and deferred financing costs		1,941	1,940
Loss on extinguishment of debt	[1]	831	0
Deferred income taxes		8,210	15,433
Share-based compensation expense	[2]	18,204	14,327
Loss (gain) on disposal of assets		(4,018)	0
Other, net		(12)	6,414
Net changes in operating assets and liabilities, net of acquisitions:
Accounts receivable		(116,768)	(85,474)
Inventories		(322,954)	(14,604)
Other assets		(6,874)	2,543
Accounts payable		269,951	11,624
Accrued wages and employee benefits		4,497	11,793
Other accrued liabilities		49,987	38,211
Excess tax benefits from equity awards		(26,880)	(6,222)
Net cash provided by operating activities		349,404	268,310
Investing activities
Proceeds from sale of property and equipment		182	26
Proceeds from sale of investment		4,968	0
Proceeds from beneficial interests in securitization transactions		2,240	1,998
Contribution to equity method investment		(781)	0
Expenditures for property and equipment		(87,456)	(33,940)
Acquisition of businesses, net of cash acquired		(465,926)	(22,815)
Net cash used in investing activities		(546,773)	(54,731)
Financing activities
Proceeds from short-term borrowings		127,816	198,087
Proceeds from long-term borrowings		50,000	297
Repayments of short-term borrowings		(105,206)	(210,854)
Repayments of long-term borrowings and finance lease obligations		(54,889)	(3,584)
Payment of contingent acquisition consideration		(3,750)	(4,000)
Payment of debt issuance costs		(1,185)	0
Purchase of additional ownership interest		(27,164)	0
Taxes paid related to equity awards		(49,569)	(13,533)
Proceeds from exercise of stock options		30,502	11,991
Net cash used in financing activities		(33,445)	(21,596)
Effect of exchange rate changes on cash and cash equivalents		(588)	(922)
Net increase (decrease) in cash and cash equivalents		(231,402)	191,061
Cash and cash equivalents at beginning of period		655,128	322,883
Cash and cash equivalents at end of period		$ 423,726	$ 513,944

[1] Represents the non-cash write-off of original issue discount and deferred financing costs due to voluntary prepayment of Term Loan debt.

[2] Represents share-based compensation expense to account for stock options, restricted stock and other stock awards over their respective vesting periods.